Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 9/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236630 | 0.91 | MEN1 (0.47) | MEN1KMT2ARXFP1TDP1PPARG | |
| SCHEMBL16236264 | 0.88 | TDP1 (0.58) | MEN1KMT2ARXFP1TDP1ALDH1A1 | |
| SCHEMBL16236933 | 0.83 | TDP1 (0.46) | MEN1KMT2ARXFP1TDP1ALDH1A1 | |
| SCHEMBL16236331 | 0.79 | CNR2 (0.47) | MEN1KMT2AS1PR3PPARGALDH1A1 | |
| SCHEMBL822253 | 0.78 | FTO (0.50) | MEN1KMT2ARXFP1PKMKDM4E | |
| SCHEMBL1585174 | 0.73 | POLB (0.64) | KMT2APDPK1PPARGALDH1A1POLB | |
| SCHEMBL3515033 | 0.73 | AURKA (0.54) | MEN1KMT2ARXFP1TDP1KDM4E | |
| SCHEMBL1585229 | 0.73 | PPARG (0.56) | KMT2APDPK1PPARGPOLB | |
| SCHEMBL30573531 | 0.73 | PPARG (0.56) | KMT2APDPK1PPARGPOLB | |
| SCHEMBL5258314 | 0.72 | TDP1 (0.56) | MEN1KMT2ARXFP1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208035-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-10-26 | — | — | US | disclosed |
| US-9676771-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676771-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160083382-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | The United States of American, as represented by the Sec, Dept. of Health and Human Services (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083382-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | The United States of American, as represented by the Sec, Dept. of Health and Human Services (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2014186398-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208035-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | CCR8, CDK8, CHD8 | MEN1 4337/4885KMT2A 1115/4885RXFP1 628/4885 |
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | MEN1 4337/4885KMT2A 1115/4885RXFP1 628/4885 |
| US-20160083382-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | MEN1 4337/4885KMT2A 1115/4885RXFP1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.